INVEGA SUSTENNA® Common Dosing and Administration Topics
General – Initiation Dosing Rationale
Consistent with the INVEGA SUSTENNA® Prescribing Information:
- The initiation regimen for INVEGA SUSTENNA® (234 mg followed by 156 mg one week later, both administered in the deltoid muscle) was designed to rapidly attain steady-state paliperidone plasma concentrations when initiating therapy without the use of oral antipsychotic supplementation. The release profile and dosing regimen of INVEGA SUSTENNA® results in sustained therapeutic concentrations. In general, overall initiation plasma levels with INVEGA SUSTENNA® were within the exposure range observed with 6-12 mg extended-release oral paliperidone. The use of the INVEGA SUSTENNA® initiation regimen allowed patients to stay in this exposure window of 6-12 mg extended-release oral paliperidone even at trough pre-dose times (Week 1 and Week 5).
For illustrative displays of this dosing scenario, please click the link(s) below.